Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 12/20 | 0.73 |
| ▸ | HDAC1 | Q13547 | 12/20 | 0.73 |
| ▸ | HDAC7 | Q8WUI4 | 12/20 | 0.73 |
| ▸ | HDAC11 | Q96DB2 | 12/20 | 0.73 |
| ▸ | HDAC8 | Q9BY41 | 12/20 | 0.73 |
| ▸ | HDAC6 | Q9UBN7 | 12/20 | 0.73 |
| ▸ | HDAC9 | Q9UKV0 | 12/20 | 0.73 |
| ▸ | HDAC5 | Q9UQL6 | 12/20 | 0.73 |
| ▸ | HDAC3 | O15379 | 11/20 | 0.73 |
| ▸ | HDAC2 | Q92769 | 11/20 | 0.73 |
| ▸ | HDAC10 | Q969S8 | 11/20 | 0.73 |
| ▸ | NCOR1 | O75376 | 2/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.73 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.73 |
| ▸ | BRD4 | O60885 | 1/20 | 0.73 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.73 |
| ▸ | EGFR | P00533 | 1/20 | 0.73 |
| ▸ | LTA4H | P09960 | 1/20 | 0.73 |
| ▸ | NR0B1 | P51843 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1064861 | 0.98 | HDAC4 (0.77) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL312344 | 0.98 | HDAC4 (0.77) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL3806017 | 0.96 | MEN1 (0.73) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL517309 | 0.94 | HDAC4 (0.81) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL6665592 | 0.92 | HDAC4 (0.85) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL1065393 | 0.92 | HDAC4 (0.85) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL6669511 | 0.92 | HDAC4 (0.85) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL137348 | 0.92 | HDAC4 (0.85) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL6296181 | 0.90 | HDAC4 (0.75) | HDAC4HDAC1HDAC7HDAC11HDAC8 | |
| SCHEMBL7828249 | 0.89 | MAPT (0.69) | HDAC4HDAC1HDAC7HDAC11HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117105737-A | Method for synthesizing alkyl carboxylic acid compound based on olefin hydrocarboxyl | 四川大学 | 2023-11-24 | — | — | CN | disclosed |
| CN-108368102-A | 2- amino -1,3,4- thiadiazines and antifungal agent based on 2- amino -1,3,4- oxadiazines | F2G有限公司 | 2018-08-03 | — | — | CN | disclosed |
| US-9957225-B2 | Treatment of friedreich's ataxia using histone deacetylase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-05-01 | — | — | US | disclosed |
| US-9957225-B2 | Treatment of friedreich's ataxia using histone deacetylase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-05-01 | — | — | US | disclosed |
| EP-2919790-B1 | GEMCITABINE PRODRUGS AND USES THEREOF | BOYEN THERAPEUTICS INC (TW) | 2018-04-04 | — | — | EP | disclosed |
| US-9890189-B2 | Gemcitabine prodrugs and uses thereof | BoYen Therapeutics, Inc. (TW) | 2018-02-13 | — | — | US | disclosed |
| US-20170107245-A1 | GEMCITABINE PRODRUGS AND USES THEREOF | BoYen Therapeutics, Inc. (TW) | 2017-04-20 | — | — | US | disclosed |
| US-9540410-B2 | Gemcitabine prodrugs and uses thereof | BoYen Therapeutics, Inc. (TW) | 2017-01-10 | — | — | US | disclosed |
| EP-3006424-A1 | HISTONE DEACETYLASE INHIBITORS AS THERAPEUTICS FOR NEUROLOGICAL DISEASES | The Scripps Research Institute (US) | 2016-04-13 | — | — | EP | disclosed |
| EP-3006424-A1 | HISTONE DEACETYLASE INHIBITORS AS THERAPEUTICS FOR NEUROLOGICAL DISEASES | The Scripps Research Institute (US) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014078295-A1 | GEMCITABINE PRODRUGS AND USES THEREOF | BoYen Therapeutics, Inc. (TW) | 2014-05-22 | — | — | WO | disclosed |
| US-20140134160-A1 | GEMCITABINE PRODRUGS AND USES THEREOF | BoYen Therapeutics, Inc. (TW) | 2014-05-15 | — | — | US | disclosed |
| US-20130210918-A1 | TREATMENT OF FRIEDREICH'S ATAXIA USING HISTONE DEACETYLASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130210918-A1 | TREATMENT OF FRIEDREICH'S ATAXIA USING HISTONE DEACETYLASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-08-15 | — | — | US | disclosed |
| US-20110021562-A1 | TREATMENT OF FRIEDREICH'S ATAXIA USING HISTONE DEACETYLASE INHIBITORS | THE SCRIPPS RESEARCH INSTUTE (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110021562-A1 | TREATMENT OF FRIEDREICH'S ATAXIA USING HISTONE DEACETYLASE INHIBITORS | THE SCRIPPS RESEARCH INSTUTE (US) | 2011-01-27 | — | — | US | disclosed |
| US-20070219244-A1 | Histone deacetylase inhibitors as therapeutics for neurological diseases | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070219244-A1 | Histone deacetylase inhibitors as therapeutics for neurological diseases | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070219244-A1 | Histone deacetylase inhibitors as therapeutics for neurological diseases | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-09-20 | — | — | US | disclosed |
| WO-2007058927-A1 | HISTONE DEACETYLASE INHIBITORS AS THERAPEUTICS FOR NEUROLOGICAL DISEASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021562-A1 | TREATMENT OF FRIEDREICH'S ATAXIA USING HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC4, HDAC6 | HDAC4 2/4885HDAC1 1/4885HDAC7 10/4885 |
| US-20130210918-A1 | TREATMENT OF FRIEDREICH'S ATAXIA USING HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC4, HDAC6 | HDAC4 2/4885HDAC1 1/4885HDAC7 10/4885 |
| US-20070219244-A1 | Histone deacetylase inhibitors as therapeutics for neurological diseases | HDAC5, HDAC1, HDAC6 | HDAC4 5/4885HDAC1 2/4885HDAC7 8/4885 |
| US-20140134160-A1 | GEMCITABINE PRODRUGS AND USES THEREOF | CCNO, ABCB1, ABCC3 | HDAC4 2134/4885HDAC1 1019/4885HDAC7 1736/4885 |
| US-20170107245-A1 | GEMCITABINE PRODRUGS AND USES THEREOF | CCNO, ABCB1, ABCC3 | HDAC4 2134/4885HDAC1 1019/4885HDAC7 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.